Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia

BACKGROUND: In preclinical studies the heat shock protein 90 (Hsp90) inhibitor tanespimycin induced down-regulation of checkpoint kinase 1 (Chk1) and other client proteins as well as increased sensitivity of acute leukemia cells to cytarabine. We report here the results of a phase I and pharmacologi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kaufmann, Scott H., Karp, Judith E., Litzow, Mark R., Mesa, Ruben A., Hogan, William, Steensma, David P., Flatten, Karen S., Loegering, David A., Schneider, Paula A., Peterson, Kevin L., Maurer, Matthew J., Smith, B. Douglas, Greer, Jacqueline, Chen, Yuhong, Reid, Joel M., Ivy, S. Percy, Ames, Matthew M., Adjei, Alex A., Erlichman, Charles, Karnitz, Larry M.
Formato: Artigo
Idioma:Inglês
Publicado: Ferrata Storti Foundation 2011
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3208679/
https://ncbi.nlm.nih.gov/pubmed/21791475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.049551
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares